financetom
Business
financetom
/
Business
/
Soccer-Ten Hag blames poor decisions for Man United's shocking defeat to Chelsea
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Soccer-Ten Hag blames poor decisions for Man United's shocking defeat to Chelsea
Apr 4, 2024 6:20 PM

April 4 (Reuters) - Manchester United ( MANU ) coach Erik Ten Hag expressed frustration and blamed costly mistakes and poor decision-making for his side conceding two stoppage-time goals against Chelsea to lose 4-3 on Thursday.

Ten Hag said his team deserved to win at Stamford Bridge, after rallying from a two-goal deficit with a brace from Alejandro Garnacho and a goal from Bruno Fernandes.

Individual errors, however, led them to defeat just a few days after his team conceded a last-gasp equaliser to Brentford in a 1-1 draw to move further away from a top-four Premier League finish. Man U now sits at sixth with 48 points.

"I had the feeling we were dominating the game, got ourselves into a winning position, scoring great goals," Ten Hag told reporters.

"Then, in stoppage time, we didn't manage to win. Of course it's frustrating.

"We made individual errors that cost us the game. The players know their jobs and they didn't make the right decisions. We have to read when to keep the ball, to pass, move and switch the play when we are winning.

"In five days we dropped five points. That is unacceptable. We gave away a game we should have won."

The Dutch manager said injury absences of key players have dampened his team's performance, but he is confident his players will step up on Sunday when they host leaders Liverpool.

"(Raphael) Varane, (Jonny) Evans, Also Casemiro we have to take off. That doesn't help. You need these types to show leadership and what to do," he said.

"I don't know if they will play on Sunday. The team will be there on Sunday. They have character. They showed it today, fighting ourselves into the game."

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved